425: Indivior/Supernus Merger: Supplemental Disclosures Issued

Indivior Pharmaceuticals, Inc. has issued supplemental disclosures regarding its merger with Supernus Pharmaceuticals, Inc., addressing recent litigation and providing updated financial advisor analysis.

Summary

• Indivior Pharmaceuticals, Inc. (Indivior) is providing supplemental disclosures related to its previously announced merger with Supernus Pharmaceuticals, Inc. (Supernus).
• This filing is an update to the definitive joint proxy statement/prospectus filed on August 28, 2026.
• The supplemental disclosures are made to address demand letters and complaints filed by purported Supernus stockholders alleging disclosure deficiencies.
• Supernus believes these claims are without merit but is providing the supplemental information to avoid litigation burden and potential merger delays.
• Updated financial advisor analysis from Cantor Fitzgerald regarding the merger's valuation for both Supernus and Indivior is included.
• Key financial figures for Supernus include estimated cash of $372 million and no debt, while Indivior has estimated cash of $249 million and debt of $500 million.
• Special meetings for stockholders of both companies to vote on the merger are scheduled for October 15, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily focused on supplemental disclosures for a pending merger. While it addresses litigation concerns, it doesn't introduce new material financial performance data.

Positives

• The supplemental disclosures aim to resolve litigation concerns, potentially clearing a path for the merger to proceed without further delays.
• Updated financial advisor analysis provides more granular detail on valuation methodologies for both Supernus and Indivior.
• Indivior has an estimated $249 million in cash and $500 million in debt, while Supernus has an estimated $372 million in cash and no debt, providing a clearer picture of their financial positions pre-merger.

Negatives

• The need for supplemental disclosures arises from litigation, indicating potential shareholder dissatisfaction or perceived inadequacies in the original filings.
• The $1 billion Special Dividend to be paid by Indivior will reduce its cash position and increase the combined company's debt burden.
• The fixed exchange ratio for the merger means it will not be adjusted for changes in the market price of either company's shares.

Risks

• The risk that the proposed merger may not be completed in a timely manner or at all.
• Failure to obtain required approvals from Supernus or Indivior stockholders.
• Failure or delay in obtaining required regulatory approvals, or the imposition of unfavorable conditions.
• The possibility of a competing or superior acquisition proposal.
• The effect of additional indebtedness incurred to fund the Special Dividend on the combined company.
• Business disruption resulting from the announcement or pendency of the transaction.
• Diversion of management's attention and resources from ongoing business operations.
• Difficulties and costs of integrating the two businesses.

Future Outlook

The filing does not provide new forward-looking statements beyond those in the definitive joint proxy statement/prospectus, which discusses risks related to the merger completion, regulatory approvals, integration, and potential business disruptions.

Management Comments

• Supernus believes that the claims asserted in the Demand Letters and Complaints are without merit and that no supplemental disclosure to the definitive joint proxy statement/prospectus is or was required under any applicable law, rule or regulation.
• Supernus denies that it has violated any law or breached any duty to its stockholders, and denies all of the allegations in the Demand Letters and Complaints.
• Solely to eliminate the burden, expense and uncertainty of litigation, to moot disclosure claims asserted in the Demand Letters and Complaints, and to avoid the risk that the Demand Letters or Complaints may delay or otherwise adversely affect the Merger, and without admitting any liability or wrongdoing, Supernus and Indivior have determined to voluntarily supplement the definitive joint proxy statement/prospectus with the disclosures set forth below.

Industry Context

StockSavvy.ai notes that supplemental disclosures in response to litigation are not uncommon in the pharmaceutical and biotechnology sectors during significant M&A activities. Companies often choose to resolve such disputes to ensure deal certainty, especially when facing potential delays to critical transactions.

Legal Proceedings

• Demand letters received from purported Supernus stockholders alleging disclosure deficiencies.
• Two complaints filed by purported stockholders of Supernus in the Supreme Court of the State of New York, County of New York, alleging disclosure deficiencies.

Stakeholder Impact

• Shareholders of Indivior and Supernus will vote on the merger, with the outcome determining the future structure of the combined entity.
• The $1 billion Special Dividend by Indivior will impact its cash reserves, potentially affecting its financial flexibility post-merger.
• Employees of both companies may face integration challenges and potential changes in roles or organizational structure.
• Customers and suppliers may experience changes in business relationships and operational procedures following the merger.

Next Steps

• Stockholders of Indivior and Supernus will vote on the Merger at their respective special meetings on October 15, 2026.
• The merger is subject to the satisfaction of other closing conditions.

Key Dates

Keywords

Merger, Supplemental Disclosure, Litigation, Valuation, Financial Advisor, Proxy Statement, Stockholder Meeting, Indivior, Supernus